Literature DB >> 3539046

The chemotherapy of onchocerciasis. XI. A double-blind comparative study of ivermectin, diethylcarbamazine and placebo in human onchocerciasis in northern Ghana.

K Awadzi, K Y Dadzie, H Schulz-Key, H M Gilles, A J Fulford, M A Aziz.   

Abstract

Fifty-nine onchocerciasis patients with ocular involvement were randomly assigned to receive either 12 mg of ivermectin in a single dose or 1300 mg of diethylcarbamazine over eight days or matching placebo capsules. Detailed standardized follow-up examination was carried out for one year. Both ivermectin and diethylcarbamazine rapidly reduced skin microfilarial counts to a similar extent over six months, after which counts increased significantly more with diethylcarbamazine. Diethylcarbamazine rapidly eliminated microfilariae from the eye, while ivermectin did so over six months. Reactions to treatment were more severe with diethylcarbamazine, which also produced clinical ocular deficiency in two patients. Ivermectin produced intra-uterine sequestration and degeneration of microfilariae in adult worms, which may account for its ability to produce prolonged suppression of skin microfilariae. Ivermectin proved superior to diethylcarbamazine in safety, tolerance and efficacy, but further work is needed to assess fully its effects in patients with heavy intraocular microfilarial loads.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3539046     DOI: 10.1080/00034983.1986.11812044

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  16 in total

Review 1.  Diethylcarbamazine in the treatment of patients with onchocerciasis.

Authors:  K Awadzi; H M Gilles
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

Review 2.  Anthelminthic agents: some recent developments and their clinical application.

Authors:  G C Cook
Journal:  Postgrad Med J       Date:  1991-01       Impact factor: 2.401

3.  Decrease in adverse reactions after repeated ivermectin treatment in onchocerciasis.

Authors:  A Van der Lelij; A Rothova; N Klaassen-Broekema; W R Wilson; R F Barbe; J S Stilma
Journal:  Doc Ophthalmol       Date:  1990-10       Impact factor: 2.379

4.  Identifying sub-optimal responses to ivermectin in the treatment of River Blindness.

Authors:  Thomas S Churcher; Sébastien D S Pion; Mike Y Osei-Atweneboana; Roger K Prichard; Kwablah Awadzi; Michel Boussinesq; Richard C Collins; James A Whitworth; María-Gloria Basáñez
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-17       Impact factor: 11.205

Review 5.  Ivermectin. A review of its antifilarial activity, pharmacokinetic properties and clinical efficacy in onchocerciasis.

Authors:  K L Goa; D McTavish; S P Clissold
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

6.  Effect of single-dose ivermectin therapy on human Onchocerca volvulus infection with onchocercal ocular involvement.

Authors:  H S Newland; A T White; B M Greene; S A D'Anna; E Keyvan-Larijani; M A Aziz; P N Williams; H R Taylor
Journal:  Br J Ophthalmol       Date:  1988-08       Impact factor: 4.638

7.  Effect of ivermectin on filariae of Mastomys natalensis.

Authors:  U R Rao; R Chandrashekar; D Subrahmanyam
Journal:  Parasitol Res       Date:  1990       Impact factor: 2.289

8.  Onchocerca volvulus-specific antibody and cytokine responses in onchocerciasis patients after 16 years of repeated ivermectin therapy.

Authors:  C S Mai; D M Hamm; M Banla; A Agossou; H Schulz-Key; C Heuschkel; P T Soboslay
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

Review 9.  Onchocerciasis.

Authors:  H R Taylor
Journal:  Int Ophthalmol       Date:  1990-05       Impact factor: 2.031

10.  Effect of ivermectin against subperiodic Brugia malayi infection in the leaf monkey, Presbytis cristata.

Authors:  J W Mak; P L Lam; A N Rain; K Suresh
Journal:  Parasitol Res       Date:  1988       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.